Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMorten Ladekarl
About this trial
Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region.
Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Incurable, progressing and/or life-threatening cancer
Expected residual survival of at least 3 months
No efficient remaining standard treatment options
Patient recruited from the Region of Northern Jutland, Denmark
Disqualifiers
WHO Performance Status >2
Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment
Trial population
Patients with incurable, progressing and/or life-threatening cancer with an expected residual survival of at least 3 months and no efficient remaining standard treatment options. Patients are recruited from the Region of Northern Jutland, Denmark.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
3,000 Participants
are grouped into 1 trial groupGroup A: Intention-to-treat cohort
Trial outcomes
Primary outcomes
1
The fraction (in %) of patients having a tumor molecular profiling done, for whom a molecularly "druggable" variant can be identified
Total number of patients included for whom a molecular variant can be identified that potentially can be matched with a targeted drug, labelled for use in cancer, divided by total number of patients included having a tumor molecular profiling done.
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Morten Ladekarl
Lead sponsor
Aalborg University Hospital
Sponsor institution
Source ClinicalTrials.gov